Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms by Laustsen, Andreas Hougaard & Dorrestijn, Netty
 
 
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright 
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
 Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
 You may not further distribute the material or use it for any profit-making activity or commercial gain 
 You may freely distribute the URL identifying the publication in the public portal 
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
  
 
   
 
 
Downloaded from orbit.dtu.dk on: Mar 29, 2019
Integrating Engineering, Manufacturing, and Regulatory Considerations in the
Development of Novel Antivenoms
Laustsen, Andreas Hougaard; Dorrestijn, Netty
Published in:
Toxins
Link to article, DOI:
10.3390/toxins10080309
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Laustsen, A. H., & Dorrestijn, N. (2018). Integrating Engineering, Manufacturing, and Regulatory Considerations
in the Development of Novel Antivenoms. Toxins, 10(8), [309]. DOI: 10.3390/toxins10080309
toxins
Commentary
Integrating Engineering, Manufacturing, and
Regulatory Considerations in the Development of
Novel Antivenoms
Andreas Hougaard Laustsen 1,* ID and Netty Dorrestijn 2
1 Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby,
Denmark
2 Utrecht Center for Affordable Biotherapeutics, Department of Pharmaceutical Sciences, Utrecht University,
3584 CG Utrecht, The Netherlands; j.dorrestijn@uu.nl
* Correspondence: ahola@bio.dtu.dk; Tel.: +45-2988-1134
Received: 7 July 2018; Accepted: 27 July 2018; Published: 31 July 2018


Abstract: Snakebite envenoming is a neglected tropical disease that requires immediate attention.
Conventional plasma-derived snakebite antivenoms have existed for more than 120 years and have
been instrumental in saving thousands of lives. However, both a need and an opportunity exist for
harnessing biotechnology and modern drug development approaches to develop novel snakebite
antivenoms with better efficacy, safety, and affordability. For this to be realized, though, development
approaches, clinical testing, and manufacturing must be feasible for any novel treatment modality to
be brought to the clinic. Here, we present engineering, manufacturing, and regulatory considerations
that need to be taken into account for any development process for a novel antivenom product,
with a particular emphasis on novel antivenoms based on mixtures of monoclonal antibodies. We
highlight key drug development challenges that must be addressed, and we attempt to outline
some of the important shifts that may have to occur in the ways snakebite antivenoms are designed
and evaluated.
Keywords: snakebite envenoming; antivenom; monoclonal antibodies; antivenom manufacture;
antivenom development; next-generation antivenom; antivenom regulation
Key Contribution: Development, manufacturing, and regulatory challenges are discussed for
next-generation antivenoms against snakebite envenoming.
1. Introduction
Each year, snakebite envenoming exacts a death toll of more than 100,000 victims and maims
more than 400,000 others [1]. In 2017, the World Health Organization (WHO) included snakebite
envenoming on its list of neglected tropical diseases (NTDs) [2] and initiated the process of developing
a global strategy for its prevention and treatment. Although an urgent necessity exists to increase
the availability of existing antivenoms, to create more awareness of snakebite envenoming, and to
train local healthcare personnel in treating snakebite in the affected regions [3], there is also a pressing
need for innovation in the antivenom field. Since Césaire Auguste Phisalix, Gabriel Bertrand, and
Albert Calmette simultaneously described the use of heterologous antivenom serotherapy in 1894 [4],
limited developments have been introduced to the field of snakebite envenoming therapy, where
animal-plasma-derived immunoglobulins (or fragments thereof) remain the mainstay of treatment [5].
To introduce novel therapeutic solutions in this field, the affordability of the final antivenom product
is key [6]. Antivenom researchers should thus implement careful considerations on how to reduce
both development and manufacturing costs. Cost reduction can be achieved through minimization of
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development risks, which in turn will improve the translation of novel experimental antivenoms into
approved products that enter the clinic [7].
When the lab work for the scientist often ends, namely with publication of a lead identification
for a certain target, the critical development process starts. The costs associated with this process
dwarf any cost incurred in preclinical research and development, and a failure in clinical trials will
have financially detrimental effects on an antivenom development program. It is thus essential to
evaluate new scientific advances in the light of the risks associated with safety, regulatory approval, late
stage development, and manufacture. Additionally, it is worth thoughtful evaluation regarding how
compatible a novel antivenom product is with existing manufacturing and distribution infrastructure,
as these aspects will have large implications on adaptability.
Here, we wish to highlight important market, regulatory, development, and manufacturing
aspects that are often neglected in the academic literature. In addition to safety and efficacy, we
thus wish to call for integrating engineering, manufacturing, and regulatory considerations in the
evaluation of novel antivenoms and the research programs necessary for these products (Figure 1).
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2. Considerations for Novel Antivenoms and their Markets
The production costs for (equine) blood-derived immunoglobulins is increasing in general, and
treatment or prophylaxis with blo d-derived Igs in low and middle-income cou tries (LMICs) is under
pressure [8]. This is not only the case for therapies against snakebit envenoming, but also for rabies,
tetanus, and diphtheria prophylaxis. Therefore, in 2017, the WHO conve ed a meeting to discuss
ways to explore how to replace of blood-derived immunoglobulins (Igs) for NTDs by monoclonal
antibodies (mAbs) [9]. The specific advantages of mAbs over polyclonal Igs include standardized
manufacturing processes, a globally large production capacity, and the possibility of producing these
antibodies through cell cultivation according to good manufacturing practices (GMP). These attributes
may improve scalability and decrease costs, thus improving access to and supply of safe alternatives
to polyclonal Igs [9–11]. In animal models, numerous specific bs have already demonstrated
their efficacy against snake venom toxins and even whole venom [12–18], which demonstrates that
the discovery and development of mAb-based therapeutics against snakebite envenoming is indeed
possible (a comprehensive overview of examples can be found in the reviews [5,19–21]).
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A major part of the cost for therapeutic mAbs lies in the development phase. This phase
also implicates the greatest risk and uncertainty, which is important to control to keep cost at a
minimum [7]. Shared product development in public–private partnerships (PPPs) offers an alternative
approach to conventional drug discovery by bringing together public partners (research programs
in academia, governmental organizations such as the WHO, not-for-profit private sector partners,
and philanthropists) with the for-profit private sector, such as pharmaceutical or biotech companies.
In these constellations, cost is shared among the partners, which reduces the development costs for
the new drug products, allowing for lower pricing for the benefit of the end payer (typically a public
partner). Such constellations have previously been successful in bringing malaria vaccines to the
market [22].
The global antivenom market, including antivenoms against scorpions and spiders, was in 2016
valued at USD 1.17 billion and is expected to grow to just under USD 1.58 billion by 2022 [23]. The
snakebite antivenom market is segmented by geographical areas and the snake species present in these
areas. The Australian and North American market represent the lion’s share of the global antivenom
market due to the establishment of poison control centers and healthcare facilities in these regions, in
addition to the willingness of payers to reimburse antivenom costs in the healthcare sector. However,
the major snakebite burden exists in the Middle East, Africa, Asia, Oceania, and Latin America, where
snakebite envenoming is a disease related to poverty [24–27]. This complicates the forecasting of formal
market sizes for snakebite antivenom for LMICs due to reimbursement uncertainties. Nevertheless, a
clear need for antivenom exists in these regions, where between 1.8 and 2.7 million people each year
are afflicted with snakebite envenoming [1].
Plasma-derived antivenoms are manufactured to be specific against certain snake species and
thus have specific regional markets based on the geographical occurrence of the snake species, whose
venoms can be neutralized by given antivenoms (potentially including other snake species for which
the antivenom is paraspecific). The fundamental reason for this is that antivenoms comprise antibodies
that are raised in direct response to the venoms included in the immunization mixture employed in
their manufacture. This has the implication that venom compositions have a determining role for
the immunological response raised in the production animal, and therefore affect the final antibody
composition of the antivenom [28]. This situation is different for future novel antivenoms based on
specifically selected mAbs. Here, antibodies are discovered and carefully selected against specific
isolated toxins using biotechnological methods [29] and guided by omics technologies [21] (particularly
toxicovenomics [30–32]), which may possibly also offer the possibility of developing antibodies
that have broad specificity against entire toxin subfamilies [28]. This may allow for novel rational
design strategies that provide the possibility of developing mAb-based antivenoms with the ability to
neutralize venoms from a broader range of species across a larger geographic area, as the antibody
compositions of such antivenoms can be tailored to specifications. Therefore, the market sizes for
mAb-based antivenoms cannot be estimated in exactly the same way as plasma-derived antivenoms,
but instead require a new view. In this regard, it is likely that the market sizes for mAb-based
antivenoms may supersede those of plasma-derived antivenoms due to the possibility of expanded
species coverage.
3. Development and Manufacturing Aspects
For any molecule to be considered relevant as a therapeutic, it must be manufacturable at large
scale and at a cost that is within the limits of what the end payer is willing and able to cover. For
many diseases that affect high-income countries, the requirement for low-cost manufacturing may
not be as critical as for diseases that mainly affect impoverished nations. Unfortunately for snakebite
envenoming, most victims live in poor, rural areas of the tropics, and snakebite has been shown in
many places to be directly correlated with poverty and lack of proper access to healthcare [24–26]. This
puts a strong demand on the cost-effectiveness for new snakebite envenoming therapies [33] and may
indeed prevent non-standard therapeutic molecules requiring specialized and intricate manufacturing
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processes from ever being able to enter the market. This implies that “stand-alone leads” that only
target one or few toxins within the same toxin family, and which cannot easily be modified to target
other toxin families may not deserve further investigation than that which pure academic curiosity
allows for, as it is simply not economically feasible to develop a specialized manufacturing process for
“stand-alone leads”. As an example of a cost-competitive manufacturing approach that could be useful
in the field of recombinant antivenoms, the Sympress technology [34] has successfully been employed
to express oligoclonal mixtures of human IgGs that have entered clinical trials for indications within
oncology and autoimmunity [35–37].
To evaluate whether or not a given type of molecule could indeed be cost-effective and
cost-competitive with existing antivenoms, it is important to fully understand the cost of goods sold
(COGS) of the molecule. In much academic literature in the field of next-generation antivenom research,
claims of the low cost of a potential pharmaceutical candidate are solely based on the (presumed)
cost of upstream processes (synthesis and/or fermentation). Downstream processes, ‘fill and finish’,
and quality assurance (QA) are often not accounted for, despite that these parts of the manufacturing
process are the most expensive for many pharmaceutical products [10,38–40]. Other claims that
find their way into the academic literature include that protein expression by microbial/prokaryotic
fermentation processes is much less expensive than mammalian cell cultivation. Although this may
indeed be true for certain processes at large scale, such claims lack nuance and seem to neglect
that microbial/prokaryotic fermentation processes often require extensive chemical engineering
efforts and a more sophisticated manufacturing setup (including steel tanks fitted with cooling and
expensive ‘cleaning in place (CIP)’ procedures [39]), which in turn requires significant upfront capital
investment [41]. In contrast, mammalian cell cultivation is nowadays routinely performed using
simple, single-use disposable equipment that does not require an advanced chemical engineering
setup, and which minimizes the downtime between batches [42,43]. Additionally, as less chemical
engineering and development is needed, the time-to-market may also be shorter for therapeutics
manufactured by routine mammalian cell cultivation, which may also have an impact on cost due to
the lowering of indirect costs [41,44]. When evaluating the cost of manufacturing of a pharmaceutical
candidate, these aspects combined with the volume of production may have a large impact [10,39],
and proper cost simulations are necessary to select the most appropriate manufacturing strategy.
As a rule of thumb, for smaller production volumes, microbial/prokaryotic fermentation processes
may have difficulty in competing on cost with mammalian cell cultivation due to increased costs
for process development and higher indirect costs of production resulting from a more advanced
manufacturing setup.
As a final word on the development and manufacturing processes for novel antivenoms, it is
relevant to consider molecules for which quality control (QC) is easy to perform and validate, and
where manufacturing processes are easy to transfer to low-cost manufacturing sites. Again, this may
drastically lower the feasibility of investigating the use of non-standard therapeutic molecules for
antivenom purposes.
4. Clinical and Regulatory Aspects
To support governments and healthcare systems in tackling the challenge of snakebite
envenoming, the WHO has developed guidelines for the production, control, and regulation of
antivenom immunoglobulins [45]. However, when it comes to developing fundamentally novel
antivenoms not derived from animal plasma, a number of existing topics in these guidelines become
redundant and new topics need to be developed for products with a fundamentally different nature,
such as antivenoms based on mAbs. As a comparable example for respiratory syncytial virus (RSV),
the WHO’s Department of Immunization, Vaccines and Biologicals has developed both a research
and development technology roadmap describing the priority activities for the development, testing,
and use of products for the treatment of RSV for LMICs [46], as well as having defined the preferred
product characteristics for RSV vaccines [47].
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To facilitate the introduction of novel antivenom products, a need also exists for developing and
incorporating robust diagnostic methodologies that allow for correct identification of the snake species
responsible for a given bite. Such methodologies could either be based on novel diagnostic tests
(venom/toxin detection kits) or scoring systems and algorithms that allow physicians to differentiate
between e.g., cytoxic/hemotoxic viper envenomings and elapid neurotoxic envenomings based on
clinical manifestations [48]. Having reliable diagnostic methodologies is an absolute prerequisite
for the planning of robust clinical trials and patient stratification. On the other hand, the need for
pharmacokinetic studies may be reduced if novel antivenom products are to be based on mAbs.
After 25 years of clinical experience with therapeutic mAbs, the pharmacokinetic behavior in both
adults and children is often predictable and well-known [49], but must still be evaluated for new
mAb-based therapeutics.
Demonstrating efficacy and safety in clinical trials is difficult, expensive, and time-consuming.
Therefore, the need for venom/toxin-specific well-characterized in vitro assays and animal models to
demonstrate proof of concept and even predict efficacy before entering into clinical trials is crucial [50].
To keep the development phase affordable for novel non-plasma-derived antivenoms, a shift towards
more extensive early research and a reduction of late (clinical) stage activities should be implemented.
Developing a completely novel antivenom product will also create an opportunity for researchers to
develop and validate new in vitro assays that might replace or reduce animal studies [51].
An accelerated regulatory approval process for a mAb-based snakebite antivenom will be
challenging. National regulatory agencies (NRAs) in the LMICs should ensure that available products,
whether imported or locally manufactured, are of high quality, safe, and efficacious, and should
thus ensure that manufacturers adhere to approved standards regarding quality assurance and GMP.
To expedite regulatory processes, facilitated regulatory pathways for new medicines in emerging
economies have been implemented [52]. The European Medicines Agency (EMA) and the WHO aim to
facilitate the review process by making recommendations for approval. The EMA facilitates registration
for products that will be used outside the EU through the EMA Article 58 procedure, and the WHO
has a Prequalification Program for LMICs, enabling registration as well as procurement [53]. Taken
together, for a novel treatment modality to be used mainly in LMICs, it is crucial to start discussions
with all parties involved in the regulatory process as early as possible. Special requirements to enable
the clinical and regulatory process, such as specific assays or biomarkers for preclinical development
and diagnostic tools to stratify snakebite victims (e.g., by identifying the perpetrating snake species
responsible for a given envenoming case) to optimize early medical treatment, need to be considered as
action points in the roadmap for technical development. Furthermore, depending on the specific action
of a novel antivenom product, such assays and biomarkers should be implemented in early research
and development. Following this approach, the traditional and expensive linear development process
(phases I to IV) may even be replaced with a question-driven approach to develop an innovative and
affordable therapy against snakebite envenoming [54].
Finally, it may be highly relevant to interact both with the healthcare systems in countries with
weak economies and not-for-profit organizations to secure political backing and economic support to
subsidize snakebite antivenoms for them to be affordable for impoverished victims [3,25].
5. Conclusions and Recommendations
An urgent need exists for the provision of safe, affordable, and effective snakebite antivenoms
to victims worldwide. Part of a long-term sustainable solution may be to harness biotechnological
approaches for the development of novel antivenom products. These may possibly be based on
mixtures of human monoclonal antibodies that could directly replace the equine polyclonal antibodies
currently used in antivenoms. For a transition from conventional plasma-derived antivenoms to
novel mAb-based antivenoms to happen, a need presents itself not only to evaluate the efficacy and
safety of new products, but also to evaluate the possibility for such new products to be developed. To
facilitate this, we recommend that engineering, manufacturing, and regulatory aspects are taken into
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consideration in the research and development of novel snakebite antivenoms, as these aspects may be
either a key to success or detrimental to next-generation antivenom development plans.
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